SEC Slaps Biomet For Foreign Doctor Bribes
SEC Slaps Biomet For Foreign Doctor Bribes
(CN) - The Securities and Exchange Commission claims Biomet Inc. bribed publicly employed doctors in China, Argentina and Brazil in exchange for the doctors using its products.
Biomet is a medical device company which primarily sells orthopedic products including joint and spinal devices used by surgeons, according to the complaint, and the company saw sales totalling $664.6 million for the first quarter of this year.
According to the complaint, Biomet and a host of related entities paid bribes to doctors at publicly owned hospitals and clinics in Argentina in exchange for sales of the company's products. The doctors allegedly received 15 to 20 percent of each sale. The SEC says before 2000, and the company allegedly falsified document to evade taxes and hide the illicit payments.
"In order to conceal the illicit purpose of the payments, Biomet Argentina employees obtained phony invoices from doctors stating that the payments were for professional services or consulting when in fact no such services occurred," the complaint states.
The company allegedly labelled the payments as "consulting fees" or "commissions," but later had to record the payments as "royalties" to circumvent a law forbidding such payments to doctors in Argentina.
Officials at the company's headquarters in Indiana were aware of this practice as early as 2000, the commission claims, citing memos and other internal communications.
In August 2008, the company issued new guidelines emphasizing compliance with the Foreign Corrupt Practices Act and the company suspended payments to doctors in Argentina.
The story is much the same for Brazil and China, the commission says.
In a memo to the senior vice president and the operations manager the internal auditor wrote, "Brazilian distributor makes payments to surgeons that may be considered as a kickback. These payments are made in cash that allows the surgeon to receive income tax free." The company apparently ceased the practice in Brazil in 2008, according to the complaint.
Biomet sold its products in China through its subsidiaries Biomet China and Scandimed. The company was aware as early 2001 that doctors in China were also receiving bribes.
The paper trail of internal documents over the years indicates, according to the SEC, that the company was well aware that doctors in all three countries were being bribed and the bribes were being covered up by auditors and high ranking company personnel.
The SEC is represented Brent S. Mitchell, Tracy L. Price, Reid A. Muoio and Kara Novaco Brockmeyer.
Biomet is a medical device company which primarily sells orthopedic products including joint and spinal devices used by surgeons, according to the complaint, and the company saw sales totalling $664.6 million for the first quarter of this year.
According to the complaint, Biomet and a host of related entities paid bribes to doctors at publicly owned hospitals and clinics in Argentina in exchange for sales of the company's products. The doctors allegedly received 15 to 20 percent of each sale. The SEC says before 2000, and the company allegedly falsified document to evade taxes and hide the illicit payments.
"In order to conceal the illicit purpose of the payments, Biomet Argentina employees obtained phony invoices from doctors stating that the payments were for professional services or consulting when in fact no such services occurred," the complaint states.
The company allegedly labelled the payments as "consulting fees" or "commissions," but later had to record the payments as "royalties" to circumvent a law forbidding such payments to doctors in Argentina.
Officials at the company's headquarters in Indiana were aware of this practice as early as 2000, the commission claims, citing memos and other internal communications.
In August 2008, the company issued new guidelines emphasizing compliance with the Foreign Corrupt Practices Act and the company suspended payments to doctors in Argentina.
The story is much the same for Brazil and China, the commission says.
In a memo to the senior vice president and the operations manager the internal auditor wrote, "Brazilian distributor makes payments to surgeons that may be considered as a kickback. These payments are made in cash that allows the surgeon to receive income tax free." The company apparently ceased the practice in Brazil in 2008, according to the complaint.
Biomet sold its products in China through its subsidiaries Biomet China and Scandimed. The company was aware as early 2001 that doctors in China were also receiving bribes.
The paper trail of internal documents over the years indicates, according to the SEC, that the company was well aware that doctors in all three countries were being bribed and the bribes were being covered up by auditors and high ranking company personnel.
The SEC is represented Brent S. Mitchell, Tracy L. Price, Reid A. Muoio and Kara Novaco Brockmeyer.
Copyright by Courthouse News Service 2012